Biodexa Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Biodexa Pharmaceuticals generated cash of -$6,826,000, which is more than the previous year. Cash used in financing activities reached the amount of $10,226,000 last year. Net change in cash is therefore $3,135,000.
Cash Flow
| 2014 | -5.45M | -907K | 34.3M |
|---|---|---|---|
| 2015 | -12.42M | -1.53M | -219K |
| 2016 | -13.08M | -1.20M | 15.25M |
| 2017 | -12.95M | -1.47M | 10.27M |
| 2018 | -13.45M | 9.04M | -6.47M |
| 2019 | -6.48M | -3.80M | 18.73M |
| 2020 | -9.30M | 2.57M | 3.08M |
| 2021 | -6.00M | -278K | 8.80M |
| 2022 | -7.04M | -220K | 47K |
| 2023 | -6.82M | -265K | 10.22M |
BDRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.83M | 10.05M | 7.54M | 10.92M | 2.34M | 13.20M | 17.60M | 16.17M | 30.32M | 2.38M |
Operating activities | ||||||||||
Net income | -7.07M | -7.65M | -5.46M | -22.18M | -10.08M | -15.03M | -16.06M | -20.16M | -10.09M | -8.82M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 283K | 343K | 403K | 1.21M | 1.28M | 1.11M | 1.16M | 4.35M | 736K | 321K |
Stock-based compensation expense | 28K | 123K | 89K | 0 | -34K | 0 | 0 | 0 | 170K | 0 |
| Deferred income tax benefit | 28K | 123K | 89K | 0 | -34K | 0 | 0 | 0 | 170K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 365K | 7K | -487K | 493K | 725K | 1.03M | -968K | -242K | -1.54M | 761K |
Inventories | 0 | 0 | 0 | 0 | 0 | 347K | -202K | -237K | -62K | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -6.82M | -7.04M | -6.00M | -9.30M | -6.48M | -13.45M | -12.95M | -13.08M | -12.42M | -5.45M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -2.54M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -26K | -62K | -320K | -209K | -319K | -244K | -707K | -1.34M | -922K | -1.03M |
Acquisitions Net | 0 | 0 | 0 | 0 | -947K | 0 | 0 | 0 | -661K | 115K |
Cash generated by investing activities | -265K | -220K | -278K | 2.57M | -3.80M | 9.04M | -1.47M | -1.20M | -1.53M | -907K |
Financing activities | ||||||||||
Common Stock Issued | 10.42M | 243K | 9.03M | 9.74M | 14.10M | 0 | 5.72M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -188K | -178K | -103K | -6.18M | 3.85M | -5.88M | 4.68M | -239K | -214K | -496K |
Cash used in financing activities | 10.22M | 47K | 8.80M | 3.08M | 18.73M | -6.47M | 10.27M | 15.25M | -219K | 34.3M |
Net Change In Cash | 3.13M | -7.22M | 2.51M | -3.38M | 8.58M | -10.86M | -4.40M | 1.43M | -14.15M | 27.93M |
Cash at end of period | 5.97M | 2.83M | 10.05M | 7.54M | 10.92M | 2.34M | 13.20M | 17.60M | 16.17M | 30.32M |